Two pre-post studies evaluated the effectiveness of intrathecal administrations of mesenchymal stromal cells into the subarachnoid space in improving neuropathic pain among those with SCI. The preliminary evidence from the studies suggest that the transplantation is safe, with mild adverse events. Reduction in neuropathic pain were seen in most patients at follow-up. Evidence regarding it’s use is still limited and warrants further examination.
There is level 4 evidence that mesenchymal stromal cells may improve pain post SCI.